PharmAthene, Siga infectious news

The Delaware Court of Chancery denied a motion from Siga for partial summary judgment in PharmAthene's breach-of-contract suit against Siga. PharmAthene claims it has a right to an exclusive license to Siga's ST-246 smallpox antiviral as a result of Siga's termination of a 2006 merger agreement between the two companies. A trial is set to begin Jan. 3. ST-246 is in Phase II testing (see BioCentury, Oct. 9, 2006). ...